Emerging Opportunities to Streamline Cancer Drug Development
December 9, 2016 | Arlington, VA
The Ritz-Carlton Pentagon City | The Diplomat Room
@PresCancerPanel | #CancerRxValue

Agenda
8:00  Registration
8:30  Welcome and Introductions
9:10  Session 1, Part 1: Bringing Drugs that Add Value to Market Faster
      - Presentation: Richard Pazdur, MD, Acting Director, Oncology Center of Excellence, U.S. Food and Drug Administration (15 min)
      - Moderated Discussion (40 min)
10:10 Break
10:25 Session 1, Part 2: Bringing Drugs that Add Value to Market Faster
11:25 Session 2, Part 1: Accelerating Throughput and Learning from Clinical Trials
      - Presentation: Lisa LaVange, PhD, Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (10 min)
      - Public Comment
      - Lunch
12:45 Session 2, Part 2: Accelerating Throughput and Learning from Clinical Trials
      - Presentation: James Zwiebel, MD, Chief, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute (10 min)
      - Moderated Discussion (60 min)
1:55 Break
2:10 Session 3: Evaluating and Approving Combination Therapies
      - Presentation: Gary Gilliland, MD, PhD, President and Director, Fred Hutchinson Cancer Research Center (10 min)
      - Presentation: Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, and Chief Medical Officer, Merck Research Laboratories (10 min)
      - Moderated Discussion (60 min)
3:30 Conclusions and Cross-Cutting Recommendations
3:45 Public Comment
3:50 Wrap-up and Next Steps
4:00 Adjourn
Emerging Opportunities to Streamline Cancer Drug Development

Participant List

Margaret Anderson, MSc
Executive Director
FasterCures
@MargaretAinDC

Roy Baynes, MD, PhD
Senior Vice President and Head Global Clinical Development
Chief Medical Officer
Merck Research Laboratories
Merck & Co., Inc.

Donald A. Berry, PhD
Professor
Department of Biostatistics
The University of Texas
M. D. Anderson Cancer Center

Danielle Carnival, PhD
Chief of Staff and Senior Policy Director
White House Cancer Moonshot Task Force
Office of the Vice President

Jason V. Cristofaro, JD, PhD
Intellectual Property Program Manager
Division of Cancer Treatment and Diagnosis
National Cancer Institute

Kathleen A. Denis, PhD
Associate Vice President
The Rockefeller University

Ann M. Geiger, PhD, MPH
Chief
Healthcare Assessment Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
@NCI_AMGeiger

Gary Gilliland, MD, PhD
President and Director
Fred Hutchinson Cancer Research Center

Hill Harper, JD
Member
President’s Cancer Panel
Author, Actor, and Philanthropist
@hillharper

Clifford A. Hudis, MD, FACP
Chief Executive Officer
American Society of Clinical Oncology
@CliffordHudis

Suleika Jaouad
New York Times Columnist
Young Adult Cancer Advocate
@SuleikaJaouad

Aaron Kesselheim, MD, JD
Associate Professor of Medicine
Harvard Medical School
Director
Program on Regulation, Therapeutics, and Law
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women’s Hospital
@akesselheim

METEINGS OF THE PRESIDENT’S CANCER PANEL ARE OPEN TO THE PUBLIC

9000 Rockville Pike • Building 31, Room B2/B37 • Bethesda, Maryland 20892-2590 • Tel: 301–451–9399 • Fax: 301–451–5909
E-mail: PresCancerPanel@nih.gov • Web site: https://PresCancerPanel.cancer.gov • Twitter: @PresCancerPanel
Emerging Opportunities to Streamline Cancer Drug Development

Participant List

Lisa LaVange, PhD
Director
Office of Biostatistics
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Lori M. Minasian, MD
Deputy Director
Division of Cancer Prevention
National Cancer Institute

Shelley Fuld Nasso, MPP
Chief Executive Officer
National Coalition for Cancer Survivorship
@sfuldnasso

Richard Pazdur, MD
Acting Director
Oncology Center of Excellence
U.S. Food and Drug Administration

Vinay K. Prasad, MD, MPH
Assistant Professor
Oncology
Oregon Health & Science University
@vinayprasad82

Barbara K. Rimer, DrPH
Chair
President’s Cancer Panel
Dean and Alumni Distinguished Professor
UNC Gillings School of Global Public Health

Mace Rothenberg, MD
Chief Development Officer
Oncology
Pfizer Global Product Development
Pfizer, Inc.

Abby B. Sandler, PhD
Executive Secretary
President's Cancer Panel
Special Assistant to the Director
Rare Tumors Initiative
Center for Cancer Research
National Cancer Institute

George A. Scangos, PhD
Chief Executive Officer
Biogen

Greg Simon, JD
Executive Director
White House Cancer Moonshot Task Force
Office of the Vice President

Philip J. Stella, MD
Medical Director
Oncology Program
St. Joseph Mercy Hospital—Ann Arbor

Owen Witte, MD
Member
President’s Cancer Panel
University Professor
Director
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
University of California, Los Angeles

James Zwiebel, MD
Chief
Investigational Drug Branch
Cancer Therapy Evaluation Program
National Cancer Institute